BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Revenue of $139 million, an increase of 39% year-over-year Testing Services revenue of $119 million, an increase of 65% year-over-year Testing Services volume of approximately 75,900, an increase of 51% year-ove
